Guardant Health (GH) director’s RSU vesting adds 264 common shares

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Guardant Health director Roberto Mignone reported the vesting and settlement of 264 restricted stock units into an equal number of common shares at a price of $0.00 per share, reflecting a routine equity compensation event rather than an open-market trade.

After this derivative exercise, Mignone directly holds 4,487 shares of common stock and 8,184 restricted stock units. The vested RSUs come from an award granted on November 8, 2024 that vests 25% on the one-year anniversary of October 21, 2024, with the remaining 75% vesting monthly over the following three years.

Insider Trade Summary

264 shares exercised/converted

Mixed 2 txns

Insider MIGNONE ROBERTO

Role Director

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	264	$0.00	--
Exercise	Common Stock	264	$0.00	--

Holdings After Transaction: Restricted Stock Units — 8,184 shares (Direct); Common Stock — 4,487 shares (Direct)

Footnotes (1)

The restricted stock unit award granted on November 8, 2024 vests over a four-year period. 25% of the shares subject to such award vested on the one-year anniversary of October 21, 2024 and the remaining 75% vests monthly for the three-year period thereafter. Not applicable for Restricted Stock Units.

Form 4 Insider Transactions: What Each Field Means →

03/23/2026 - 04:19 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MIGNONE ROBERTO

(Last)

(First)

(Middle)

3100 HANOVER STREET

(Street)

PALO ALTO

CALIFORNIA

94304

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Guardant Health, Inc. [ GH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/21/2026		M		264	A	$0	4,487	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	$0	03/21/2026		M			264	⁽¹⁾	⁽²⁾	Common Stock	264	$0	8,184	D

Explanation of Responses:

1. The restricted stock unit award granted on November 8, 2024 vests over a four-year period. 25% of the shares subject to such award vested on the one-year anniversary of October 21, 2024 and the remaining 75% vests monthly for the three-year period thereafter.

2. Not applicable for Restricted Stock Units.

Remarks:

	/s/ John G. Saia, as attorney-in-fact for Roberto A. Mignone	03/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Guardant Health (GH) director Roberto Mignone report?

Director Roberto Mignone reported the vesting and exercise of 264 restricted stock units into 264 shares of Guardant Health common stock at $0.00 per share. This reflects equity compensation vesting, not an open-market purchase or sale.

How many Guardant Health (GH) shares does Roberto Mignone hold after this Form 4?

Following the reported transactions, Roberto Mignone directly holds 4,487 shares of Guardant Health common stock and 8,184 restricted stock units. These figures show his post-transaction equity position as disclosed in the Form 4 filing.

What are the vesting terms of Roberto Mignone’s Guardant Health (GH) RSU award?

The RSU award granted on November 8, 2024 vests over four years: 25% of the shares vested on the one-year anniversary of October 21, 2024, and the remaining 75% vests monthly during the following three-year period.

Was Roberto Mignone’s Guardant Health (GH) transaction an open-market buy or sell?

The Form 4 shows a derivative exercise, not an open-market buy or sell. Restricted stock units vested and converted into 264 common shares at $0.00 per share as part of equity compensation, with no open-market trading reported.

How many restricted stock units does Roberto Mignone hold in Guardant Health (GH)?

After the reported vesting, Roberto Mignone holds 8,184 restricted stock units in Guardant Health. These RSUs relate to an award granted on November 8, 2024, which vests over a four-year schedule with monthly vesting after the first anniversary.